Lynn Kramer, MD, FAAN: BAN2401 Phase IIb Clinical Study Results Published 2018-07-30 Download video MP4 360p Download video MP4 720p Recommendations 05:49 FDA fully approves Leqembi, first drug to slow progression of Alzheimer's disease 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 04:51 Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS 04:29 Givinostat's Multifactorial Mechanism of Action in Duchenne Muscular Dystrophy 01:39 BAN2401 (lecanemab) Mechanism of Action 28:56 Loneliness hurts my ME/CFS patients more than science shows - LIVE 1:04:37 T cells, cancer and immunity 19:58 The Secret Language of Doctors 05:20 Regulatory Pathways and Clinical Trials for Gene Therapy in Parkinson Disease 07:40 A Holistic Approach to Preserving Brain Health 22:18 10 quick anxiety relief techniques 04:25 Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD 23:06 8 Unexpected Ways We Self-Harm & How to Stop 05:05 Takotsubo Syndrome and the Brain Heart Connection 20:53 THE POWER OF STORY - Lynda 05:10 Dreams of Dali: 360º Video 03:57 Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC 07:48 Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease 04:03 A Call to Action to Address Disparities in Multiple Sclerosis Care 05:53 Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds Similar videos 11:32 Outstanding amyloid response to BAN2401: slowing progression in early Alzheimer’s 10:19 Clinical trial for BAN2401 in early Alzheimer’s: combining ADCOMS and Bayesian statistics 01:31 Phase II study of lecanemab in early AD 00:42 BAN2401 Study: Early Alzheimer’s Disease - First Choice Neurology - Dr. Jeffrey Gelblum 04:57 Open-label extension study of lecanemab in early Alzheimer’s disease 03:54 Eisai CEO on Alzheimer's treatment drug trial results 04:59 Lecanemab: Phase II open-label extension results 00:56 What is different about this clinical trial - First Choice Neurology - Dr. Jeffrey Gelblum 01:38 The potential of lecanemab for the treatment of early Alzheimer’s disease 13:38 Presentation of Final Results of AscenD-LB Clinical Trial 01:08 How many patients can participate in the BAN2401 Study - Dr. Jeffrey Gelblum, First Choice Neurology 01:05 BAN2401 01:28 Alzheimer’s Disease Clinical Trial Participants: Thank You 06:01 The development of lecanemab & rationale behind its unique binding profile 08:54 New Alzheimer’s Drug Shows Big Promise in Early Trial Results 23:32 014 - Biogen drops on shaky BAN2401 data! 19:45 024 - Does BAN2401 Actually Work? Upcoming Subgroup Analyses 01:56 New Drug Could Slow Down Progression Of Alzheimer’s | NBC Nightly News 01:00 What type of medication is given in the BAN2401 Study - First Choice Neurology - Dr. Jeffrey Gelblum More results